349 related articles for article (PubMed ID: 28202824)
21. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
22. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease.
Xu Y; Deng Y; Qing H
J Neurochem; 2015 Oct; 135(1):4-18. PubMed ID: 26134497
[TBL] [Abstract][Full Text] [Related]
23. Updating Our Definitions of Parkinson's Disease for a Molecular Age.
Chen-Plotkin AS; Zetterberg H
J Parkinsons Dis; 2018; 8(s1):S53-S57. PubMed ID: 30584165
[TBL] [Abstract][Full Text] [Related]
24. Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology.
Del Tredici K; Braak H
Neuropathol Appl Neurobiol; 2016 Feb; 42(1):33-50. PubMed ID: 26662475
[TBL] [Abstract][Full Text] [Related]
25. α-synuclein imaging: a critical need for Parkinson's disease research.
Eberling JL; Dave KD; Frasier MA
J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
[TBL] [Abstract][Full Text] [Related]
26. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
Halliday GM; McCann H
Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
[TBL] [Abstract][Full Text] [Related]
27. In vivo gastric detection of α-synuclein inclusions in Parkinson's disease.
Sánchez-Ferro Á; Rábano A; Catalán MJ; Rodríguez-Valcárcel FC; Fernández Díez S; Herreros-Rodríguez J; García-Cobos E; Álvarez-Santullano MM; López-Manzanares L; Mosqueira AJ; Vela Desojo L; López-Lozano JJ; López-Valdés E; Sánchez-Sánchez R; Molina-Arjona JA
Mov Disord; 2015 Apr; 30(4):517-24. PubMed ID: 25113060
[TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
29. Neuroimaging in Parkinson's disease: a future perspective.
Brooks DJ
Neurodegener Dis Manag; 2015; 5(2):105-8. PubMed ID: 25894874
[No Abstract] [Full Text] [Related]
30. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
[TBL] [Abstract][Full Text] [Related]
31. Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera E; Masliah E
Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
[TBL] [Abstract][Full Text] [Related]
32. Peripheral synuclein tissue markers: a step closer to Parkinson's disease diagnosis.
Tolosa E; Vilas D
Brain; 2015 Aug; 138(Pt 8):2120-2. PubMed ID: 26205837
[No Abstract] [Full Text] [Related]
33. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
34. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
Eschbach J; Danzer KM
Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
36. Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Buttery PC; Barker RA
Neurotherapeutics; 2020 Oct; 17(4):1539-1562. PubMed ID: 33128174
[TBL] [Abstract][Full Text] [Related]
37. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy.
Zange L; Noack C; Hahn K; Stenzel W; Lipp A
Brain; 2015 Aug; 138(Pt 8):2310-21. PubMed ID: 26017579
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic innovation in Parkinson's disease: a 2020 update on disease-modifying approaches.
Colombo D; Pnevmatikou P; Melloni E; Keywood C
Expert Rev Neurother; 2020 Oct; 20(10):1047-1064. PubMed ID: 32758042
[TBL] [Abstract][Full Text] [Related]
40. Spinal cord lesions in sporadic Parkinson's disease.
Del Tredici K; Braak H
Acta Neuropathol; 2012 Nov; 124(5):643-64. PubMed ID: 22926675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
